GlassScriptPhysician profile
Edie Lemley
NPI 1891711883
$2,212.67
in general payments reported to CMS, 2019-2025
23 companies · $643 in 2025
The $643 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2023: $532 · 2024: $839 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $501.69 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $409.04 | 2023-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $283.17 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $198.36 | 2023-2025 | Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $190.66 | 2024 | Ultomiris |
| Boston Scientific Corporation | $92.19 | 2021 | |
| Neurelis, INC. | $86.25 | 2023-2024 | Valtoco |
| Sumitomo Pharma America, INC. | $72.85 | 2023-2024 | Aptiom |
| Acadia Pharmaceuticals INC | $72.23 | 2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $59.93 | 2023-2024 | Nuedexta, Rexulti |
| Medline Industries LP | $41.53 | 2024 | Medline Industries, INC. |
| Pacira Therapeutics, INC. | $39.36 | 2021 | |
| Lilly USA, LLC | $20.76 | 2024 | Jaypirca, Verzenio |
| Novartis Pharmaceuticals Corporation | $19.64 | 2023 | |
| Horizon Therapeutics Plc | $15.72 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.46 | 2023 | Tecentriq, Polivy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.50 | 2021 | |
| Abbott Laboratories | $14.10 | 2023 | Freestyle Libre 3 |
| Sk Life Science, INC. | $14.01 | 2025 | |
| Argenx US, INC. | $13.92 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Nevro Corp. | $13.59 | 2021 | |
| Biodelivery Sciences International, INC. | $12.30 | 2021 | |
| Redhill Biopharma INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edie Lemley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.